Brontictuzumab  (Synonyms: OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody)

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma^[1][2][3].

Brontictuzumab (0-100 μg/mL) inhibits Notch1 signaling, including DLL4, JAG1/2 activity^[1].
Brontictuzumab (25 μg/mL, 4 days) reduces the levels of Notch1 intracellular domain in the HPB-ALL cell line^[1].
Brontictuzumab (25 μg/mL, 48 h) inhibits DLL4-mediated cleaved-Notch1 overexpression in MCL cells^[2].
Brontictuzumab (25 μg/mL, 48 h) blocks the increased phosphorylation of both, MEK and ERK by DLL4 stimulation in Mino cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft^[3].
Brontictuzumab (20 mg/kg, i.p., every 4 days) inhibits DLL4 induced activation of Notch1 in MCL model^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1447814-75-6

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568.  [Content Brief]

  [2]. Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446.  [Content Brief]

  [3]. Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28(2):278-88.  [Content Brief]